Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
Leiden, the Netherlands, May 30, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an […]